With its fast-growing, young population and projected pharmaceutical sales in
excess of $20 billion in 2014, countries in the Association of South East
Asian Nations (ASEAN) represent a great opportunity for Pharma.
However, with regional marketing practices, uncertain production values of
locally manufactured generics and a huge diversity in healthcare delivery
across ten nations of varying income levels, there are also great challenges.
Despite the disadvantages large multinationals face, major pharmaceutical
companies are diving into the region, focusing on revenue from new chemical
entities and developing ‘branded' generics as key investments.
But given regional dynamics, pro-generic legislation, inconsistent IPR
enforcement and local industry protection, what are the factors that the
industry can leverage to drive success?
Based on interviews with ten of the region's most experienced industry
experts, ‘Branded Generics in S.E. Asia: Current and Future Opportunities’
explores why the pharmaceutical industry is focusing on branded generics and
new chemical entity (NCE) revenues. Timely and packed with essential details,
the report describes the current state-of-play, the future of branded generics
and the physician, prescriber and patient dynamics that govern drug dispensing.
By offering insight into the complex forces at work, this comprehensive report
provides the critical intelligence necessary for success within the region.
Can Big Pharma firmly insert itself into such a vibrant but locally-dominated
market? ‘Branded Generics in S.E. Asia: Current and Future Opportunities’ has
Key Report Features
- Insight into why ASEAN markets are difficult for multinationals to
- Timely, targeting information on regional dynamics
- Discussion of ASEAN harmonization, how it is challenging regulatory and
manufacturing standards and how that will impact local players
- The role of government intervention, particularly in pro-generic
- The impact of local industry protection in creating barriers for
- Strategies the industry is employing to take advantage of quality control
- Overview of regional economics
- Gain insight into the complexity of the ASEAN region
- Deepen your understanding of the current market situation in South East
- Find out how pro-generic legislation, local industry protection and
manufacturing weaknesses have resulted in a lack of regional leaders
- Gain insight into why most - but not all - local companies won't survive
- Find out how success will be dependent upon quickly adapting to new
regulatory standards and marketing the right branded generics to suit regional
- Receive insight into major commercial opportunities
Key Questions Answered
- What are the main challenges facing Big Pharma in South East Asia?
- How can multinationals effectively gain traction in ASEAN countries?
- Who is best adapting to regional conditions and how is it being done?
- What are the conditions favouring local producers?
- Who are the key decision makers and what are the factors influencing them?
- How can multinationals adapt to changing government regulation?
- What is the net benefit of establishing relationships with local companies?
Who Would Benefit From This Report?
This report will be of value to senior pharma directors and managers with
responsibilities in the following areas:
- Executive management
- Licensing/Business development
- Market research and business intelligence
- Marketing, category and product management
- Key account and territory management
- Emerging market development
- Regulatory and government affairs
Expert Views Include:
- Manish Bajaj, Senior Director Strategy for Branded Generics Markets, Dr Reddy's, India.
- Y.S. Chua, ex Business Development Director, Sanofi, Malaysia.
- Peter Dolinsky, General Manager Medinova Asia, DKSH, Thailand.
- Dean Edwards, ex VP, Sales, Asia Pacific, IMS Health and Founder Oliver Henry Consulting.
- Andrew Howden, CEO iNova, Australia.
- Jason Humphries, Managing Director, Good Pharmaceuticals, Singapore.
- Dr. Suchitra Kataria, academic at the University of Wales, Singapore campus and previous Head Business Development and In-Licensing - Regional Strategic Development Asia Pacific at Bayer Schering Pharma, Singapore.
- Peter Keil, VP & Regional Director Asia, Alvogen, Thailand.
- Andrew Moore, VP Business Development, InnoBio Ventures, Malaysia.
- Giles Moss, AFT Pharmaceuticals S.E. Asia, Malaysia.